

## PALM INTRANET

Day : Tuesday  
Date: 8/26/2003  
Time: 15:02:58

## Inventor Name Search Result

Your Search was:

Last Name = OTTOSEN

First Name = ERIK

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>60434798</u>	Not Issued	020	12/20/2002	NOVEL AMINO BENZOPHENONE COMPOUNDS	OTTOSEN, ERIK RYTTER
<u>60315025</u>	Not Issued	020	08/28/2001	POLAR AMINO BENZOEPHENONES 614/LAC	OTTOSEN, ERIK RYTTER
<u>60169333</u>	Not Issued	159	12/06/1999	AMINO BENZOPHENONES AS INHIBITORS OF IL-1B AND TNF-A	OTTOSEN, ERIK R
<u>60144169</u>	Not Issued	159	07/16/1999	AMINO BENZOPHENONES AS INHIBITORS OF IL-1 BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
<u>60144168</u>	Not Issued	159	07/16/1999	COMPOUNDS FOR MEDICAL TREATMENT	OTTOSEN, ERIK RYTTER
<u>60144166</u>	Not Issued	159	07/16/1999	AMINO BENXOPHENONES AS INHIBITORS OF IL-1 BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
<u>60144065</u>	Not Issued	159	07/16/1999	COMPOUNDS FOR MEDICAL TREATMENT	OTTOSEN, ERIK RYTTER
<u>60144063</u>	Not Issued	159	07/16/1999	AMINO BENZOPHENONES AS INHIBITORS OF IL-1B AND TNF-@	OTTOSEN, ERIK RYTTER
<u>60144062</u>	Not Issued	159	07/16/1999	AMINO BENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK
<u>10228954</u>	Not Issued	041	08/28/2002	NOVEL AMINO BENZOEPHENONES	OTTOSEN, ERIK RYTTER
<u>10061204</u>	Not Issued	093	02/04/2002	CYANO GUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER

<u>10031075</u>	<u>6566554</u>	150	02/22/2002	AMINO BENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
<u>10031071</u>	<u>6555710</u>	150	03/15/2002	AMINO BENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
<u>10030970</u>	Not Issued	030	02/22/2002	AMINO BENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
<u>10030965</u>	Not Issued	095	02/22/2002	NOVEL AMINO BENZOPHENONES	OTTOSEN, ERIK RYTTER
<u>10030941</u>	Not Issued	090	02/22/2002	AMINO BENZOPHENONES AS INHIBITORS OF IL-BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
<u>09787532</u>	<u>6541670</u>	150	03/20/2001	AMINO BENZOPHENONES AS INHIBITORS OF IL 1B AND TNF	OTTOSEN, ERIK RYTTER
<u>09424655</u>	<u>6121297</u>	150	11/26/1999	CYANO GUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER
<u>09424631</u>	<u>6346520</u>	150	11/26/1999	CYANO GUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER
<u>09424630</u>	<u>6197797</u>	150	11/26/1999	CYANO GUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER
<u>09424581</u>	<u>6303641</u>	150	11/26/1999	CYANO AMIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER
<u>09341923</u>	<u>6313174</u>	150	07/21/1999	AMINO BENZOPHENONES AS INHIBITORS OF INTERLEUKIN AND TNF	OTTOSEN, ERIK RYTTER
<u>08411634</u>	<u>5554599</u>	150	04/11/1995	22-THIO VITAMIN D DERIVATIVES	OTTOSEN, ERIK R

Inventor Search Completed: No Records to Display.

Search Another:  
Inventor

Last Name

Ottosen

First Name

Erik

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

10/030,970



=> d ibib abs hitstr 1-3

CAS- 8/26/03


X L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2003:173569 CAPLUS  
DOCUMENT NUMBER: 138:221352  
TITLE: Preparation of (phenylamino)benzophenones for  
treatment of inflammatory diseases  
INVENTOR(S): Ottosen, Erik Rytter; Horneman, Anne Marie; Liang,  
Xifu  
PATENT ASSIGNEE(S): Leo Pharma A/S, Den.  
SOURCE: PCT Int. Appl., 132 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018535	A2	20030306	WO 2002-DK557	20020826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003119902 A1 20030626 US 2002-228954 20020828  
PRIORITY APPLN. INFO.: US 2001-315025P P 20010828  
DK 2002-189 A 20020208  
OTHER SOURCE(S): MARPAT 138:221352  
GI



- AB Title compds. I [wherein X = O, S, or N(ORC); R1 = halo, OH, SH, CF3, NH2, alkyl, olefinic group, alkoxy, alkylthio, alkylamino, alkoxy carbonyl, CN, CONH2, Ph, or NO2; R2 = H or R1; R3 = H, halo, OH, SH, CF3, CN, CO2H, carbamoyl, NO2, alkyl, olefinic group, cyclic hydrocarbon, alkoxy, alkylthio, alkoxy carbonyl, or Ph; R4 = H, alkyl, olefinic group, cyclic hydrocarbon, or CO2CRdReOCOR14; R5 = H or R1; R6 = (un)substituted (alkyl)heterocyclyl, (alkyl)cyclic hydrocarbon, alkyl, olefinic group, alkynyl, Y1R21, Y2R22, or Y4R24; R14 = (un)substituted alkyl, olefinic group, cyclic hydrocarbon, heterocyclyl, or alkynyl; Y1 = NRACSNRb, CO, CS, CSO, COS, CS2, OCS, OCO, NRACSO, SO2O, SO2NRA, N=CRA, etc.; R21 = (un)substituted (alkyl)heterocyclyl, (alkyl)cyclic hydrocarbon, alkyl, olefinic group, or alkynyl; Y2 = O, S, CO2, or CONRA; R22 and R24 = independently (un)substituted (alkyl)heterocyclyl, (alkyl)cyclic hydrocarbon, alkynyl, alkyl, or olefinic group; Y4 = NRACONRbCHRC, NRACONRbSO2, NRA, etc.; Ra, Rb, and Rc = independently H or (un)substituted alkyl, olefinic group, cyclic hydrocarbon, aryl, heterocyclyl, or alkynyl; Rd and Re = independently (un)substituted H, alkyl, olefinic group, or cyclic hydrocarbon; and pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as inhibitors of interleukin 1.beta. and tumor necrosis factor .alpha. (no data). For example, (4-amino-2-chlorophenyl)(2-methylphenyl)methanone was coupled with 2-[2-(2-bromophenyl)ethoxy]tetrahydro-2H-pyran in the presence of Cs2CO3, Pd2(dba)3, and rac-BINAP in dioxane to give II. I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory diseases, such as asthma, allergy, arthritis, gout, atherosclerosis, psoriasis, AIDS, osteoporosis, and acne (no data).
- IT **500875-79-6P**, 2-[[[5-Bromo-2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]amino]ethyl 2-methylacrylate  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (antiinflammatory agent; prepn. of (phenylamino)benzophenones for treatment of inflammatory diseases)
- RN 500875-79-6 CAPLUS
- CN 2-Propenoic acid, 2-methyl-, 2-[[[5-bromo-2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]amino]ethyl ester (9CI)  
 (CA INDEX NAME)





*Inventor*

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:63961 CAPLUS  
 DOCUMENT NUMBER: 134:115759  
 TITLE: Preparation of aminobenzophenones as inhibitors of IL-1.beta. and TNF-.alpha.  
 INVENTOR(S): Ottosen, Erik Rytter  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.

10/030,970

SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005751	A1	20010125	WO 2000-DK387	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1210325	A1	20020605	EP 2000-943701	20000711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			US 1999-144062P	P 19990716
			WO 2000-DK387	W 20000711
OTHER SOURCE(S):			MARPAT 134:115759	
GI				



AB The title compds. [I; R1, R2 = halo, OH, SH, etc.; R3 = H, halo, OH, etc.; R4 = H, alkyl, allyl; Q = a bond, SO2, CR6R7OC:O (wherein R6, R7 = H, CF3, alkyl); Y = alkyl, alkenyl, cycloalkyl, etc.; X = O, S] which are able to inhibit the prodn. of IL-1.beta., TNF-.alpha. and PMN-superoxide, were prepd. and formulated. Thus, reacting 4-(2-aminophenylamino)-2-chloro-2'-

10/030,970


methylbenzophenone with cyclohexyl isocyanate in EtOAc afforded the urea II which showed IC<sub>50</sub> of 13 nM and of 5.0 nM against IL-1.β. and TNF-α. prodn., resp.

IT 321438-17-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of aminobenzophenones as inhibitors of IL-1.β. and TNF-α.)

RN 321438-17-9 CAPLUS

CN .β.-Alanine, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 321438-07-7P 321438-08-8P 321438-09-9P  
321438-10-2P 321438-11-3P 321438-12-4P  
321438-13-5P 321438-14-6P 321438-15-7P  
321438-16-8P 321438-18-0P 321438-19-1P  
321438-20-4P 321438-21-5P 321438-22-6P  
321438-23-7P 321438-24-8P 321438-25-9P  
321438-26-0P 321438-27-1P 321438-28-2P  
321438-29-3P 321438-30-6P 321438-31-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of aminobenzophenones as inhibitors of IL-1.β. and TNF-α.)

RN 321438-07-7 CAPLUS


CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 321438-08-8 CAPLUS


CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

10/030,970




RN 321438-09-9 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-phenyl-(9CI) (CA INDEX NAME)




RN 321438-10-2 CAPLUS

CN Urea, N-butyl-N'-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-phenyl-(9CI) (CA INDEX NAME)



RN 321438-11-3 CAPLUS


CN Benzenesulfonamide, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]-4-methyl-(9CI) (CA INDEX NAME)



RN 321438-12-4 CAPLUS


10/030,970

CN Benzenesulfonamide, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 321438-13-5 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 321438-14-6 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 321438-15-7 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)






10/030,970


RN 321438-16-8 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-methyl-  
(9CI) (CA INDEX NAME)




RN 321438-18-0 CAPLUS

CN Urea, N-[5-bromo-2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-19-1 CAPLUS


CN .beta.-Alanine, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 321438-20-4 CAPLUS


CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]-5-fluorophenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

10/030,970




RN 321438-21-5 CAPLUS

CN Urea, N-[5-bromo-2-[[4-(4-butyl-2-methylbenzoyl)-3-chlorophenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-22-6 CAPLUS


CN Urea, N-[5-bromo-2-[[3-chloro-4-(2,5-dimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-23-7 CAPLUS


CN Urea, N-[5-bromo-2-[[3-chloro-4-(3-chloro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

10/030,970




RN 321438-24-8 CAPLUS

CN Urea, N-[5-bromo-2-[[3-chloro-4-(4-ethoxy-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 321438-25-9 CAPLUS

CN Urea, N-[5-bromo-2-[[3-ethoxy-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-26-0 CAPLUS


CN Urea, N-[5-bromo-2-[[3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



10/030,970


RN 321438-27-1 CAPLUS

CN Urea, N-[5-bromo-2-[[3-chloro-4-(2,3-dimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 321438-28-2 CAPLUS

CN Urea, N-[5-bromo-2-[[3-fluoro-4-(4-methoxy-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-29-3 CAPLUS


CN Urea, N-[5-bromo-2-[[3-chloro-4-(2,4,5-trimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-30-6 CAPLUS


CN Urea, N-[5-bromo-2-[[3-chloro-4-(4-fluoro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

10/030,970



RN 321438-31-7 CAPLUS

CN Urea, N-[5-bromo-2-[[[3-fluoro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:527309 CAPLUS

DOCUMENT NUMBER: 129:148822

TITLE: Preparation and formulation of aminobenzophenones as inhibitors of interleukin and TNF

INVENTOR(S): Ottosen, Erik Rytter; Rachlin, Schneur

PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832730	A1	19980730	WO 1998-DK8	19980108
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9854781	A1	19980818	AU 1998-54781	19980108
AU 733561	B2	20010517		
EP 966424	A1	19991229	EP 1998-900270	19980108

10/030,970

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI


NZ 336754	A	20010330	NZ 1998-336754	19980108
JP 2001511771	T2	20010814	JP 1998-531499	19980108
RU 2200153	C2	20030310	RU 1999-118221	19980108
US 6313174	B1	20011106	US 1999-341923	19990721

PRIORITY APPLN. INFO.:

GB 1997-1453	A	19970124
WO 1998-DK8	W	19980108

OTHER SOURCE(S): MARPAT 129:148822

GI



AB The title compds. I [R1 and R2 stand independently for one or more, similar or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, cyano, carboxy, carbamoyl, Ph, or nitro; R3 stands for hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, Ph, cyano, carboxy, or carbamoyl; R4, R5 and R6 stand independently for hydrogen, trifluoromethyl, alkyl, carbamoyl, alkoxycarbonyl, or alkyloxo, the C-content of which can be from 1 to 5; X stands for oxygen, NOH, NO-alkyl, dialkoxy, cyclic dialkoxy, dialkylthio, or cyclic dialkylthio, the C-content of which can be from 1 to 5] are prepd. The present compds. are of value in the human and veterinary practice as systemic and topical therapeutic agents for the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, proliferative and inflammatory skin disorders, such as psoriasis, and atopic dermatitis. In an in vitro test using human polymorphonuclear granulocytes, 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone in vitro showed IC50 of 13 nM and 7.1 nM against the prodn. of IL-1.β and TNF-α, resp. In the above test, 4-(2-aminophenylamino)benzophenone (II) in vitro showed IC50 of 250 nM and 790 nM against the prodn. of IL-1.β and TNF-α, resp. In the 12-O-tetradecanoylphorbol-13-acetate induced murine skin inflammation model, II showed activity equal to hydrocortisone.

IT 210965-94-9P 210966-54-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminobenzophenones as inhibitors of interleukin and TNF)

RN 210965-94-9 CAPLUS


CN Urea, N-[2-[(4-benzoylphenyl)amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)

10/030,970



RN 210966-54-4 CAPLUS

CN Urea, N-[2-[(4-benzoylphenyl)amino]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:01:13 ON 26 AUG 2003)

FILE 'REGISTRY' ENTERED AT 15:01:19 ON 26 AUG 2003

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 28 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:02:10 ON 26 AUG 2003


L4 3 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR

10/030,970



G1 O,S

Structure attributes must be viewed using STN Express query preparation.